Sugi Predict

Sugi Predict / Compounds / SCHEMBL1748833

SCHEMBL1748833

SCHEMBL1748833

COc1cc2c(-c3cc4cccnc4n3S(=O)(=O)c3ccc(C)cc3)cn(C)c2cc1OCCOC(C)=O

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 1/20 0.42
▸ PTGDR2 Q9Y5Y4 6/20 0.38
▸ CCNE1 P24864 2/20 0.37
▸ CDK2 P24941 2/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ NOD2 Q9HC29 1/20 0.35
▸ NOD1 Q9Y239 1/20 0.35
▸ ENPP3 O14638 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ PCSK9 Q8NBP7 1/20 0.33
▸ PDE4A P27815 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ PDE4C Q08493 1/20 0.33
▸ PDE4D Q08499 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749119 0.91 IGF1R (0.44) IGF1RPTGDR2CCNE1CDK2L3MBTL1
SCHEMBL1778785 0.90 IGF1R (0.50) IGF1RPTGDR2CCNE1CDK2L3MBTL1
SCHEMBL1749120 0.89 IGF1R (0.44) IGF1RPTGDR2CCNE1CDK2L3MBTL1
SCHEMBL1748634 0.89 IGF1R (0.44) IGF1RPTGDR2CCNE1CDK2L3MBTL1
SCHEMBL1748899 0.89 IGF1R (0.44) IGF1RPTGDR2CCNE1CDK2L3MBTL1
SCHEMBL1749000 0.89 IGF1R (0.44) IGF1RPTGDR2CCNE1CDK2L3MBTL1
SCHEMBL1749102 0.89 IGF1R (0.42) IGF1RPTGDR2CCNE1CDK2L3MBTL1
SCHEMBL1749036 0.88 PTGDR2 (0.43) IGF1RPTGDR2CCNE1CDK2L3MBTL1
SCHEMBL1749053 0.86 IGF1R (0.44) IGF1RPTGDR2CCNE1CDK2L3MBTL1
SCHEMBL1779402 0.86 IGF1R (0.44) IGF1RPTGDR2CCNE1CDK2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968566-B2 Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-06-28 — — US disclosed
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2009-09-17 — — US disclosed
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 — — US disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885PTGDR2 806/4885CCNE1 494/4885
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885PTGDR2 806/4885CCNE1 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.